These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Panresistant cytomegalovirus in a kidney transplant recipient. Yost SE; Echeverria A; Jie T; Kaplan B Pharmacotherapy; 2014 Jan; 34(1):e1-3. PubMed ID: 24277702 [TBL] [Abstract][Full Text] [Related]
25. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients. Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242 [TBL] [Abstract][Full Text] [Related]
26. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790 [TBL] [Abstract][Full Text] [Related]
27. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523 [TBL] [Abstract][Full Text] [Related]
28. Preemptive therapy for cytomegalovirus disease in allogeneic stem cell transplant recipients. de la Cruz-Vicente F; Cerezuela Martinez P; Gil-Espárraga E; Martin Aguilera C; Aguilar Guisado M; Parody Ruiz-Berdejo R; Cisneros Herreros JM; Urbano-Ispizua A; Espigado Tocino I Transplant Proc; 2008 Nov; 40(9):3102-3. PubMed ID: 19010207 [TBL] [Abstract][Full Text] [Related]
30. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. Allice T; Busca A; Locatelli F; Falda M; Pittaluga F; Ghisetti V J Antimicrob Chemother; 2009 Mar; 63(3):600-8. PubMed ID: 19147520 [TBL] [Abstract][Full Text] [Related]
31. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience. Selvey LA; Lim WH; Boan P; Swaminathan R; Slimings C; Harrison AE; Chakera A BMC Infect Dis; 2017 Jul; 17(1):501. PubMed ID: 28716027 [TBL] [Abstract][Full Text] [Related]
32. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient. García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746 [TBL] [Abstract][Full Text] [Related]
33. Clinical aspects of CMV infection after stem cell transplantation. Hebart H; Einsele H Hum Immunol; 2004 May; 65(5):432-6. PubMed ID: 15172442 [TBL] [Abstract][Full Text] [Related]
34. Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. Martin M; Goyette N; Ives J; Boivin G J Clin Virol; 2010 Apr; 47(4):321-4. PubMed ID: 20138805 [TBL] [Abstract][Full Text] [Related]
35. Antiviral treatment of cytomegalovirus infection. Ahmed A Infect Disord Drug Targets; 2011 Oct; 11(5):475-503. PubMed ID: 21827432 [TBL] [Abstract][Full Text] [Related]
36. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors. Shah T; Lai WK; Mutimer D Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091 [TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442 [TBL] [Abstract][Full Text] [Related]
38. Case study: rapid emergence of a cytomegalovirus UL97 mutant in a heart-transplant recipient on pre-emptive ganciclovir therapy. Gilbert C; LeBlanc MH; Boivin G Herpes; 2001 Nov; 8(3):80-2. PubMed ID: 11867025 [TBL] [Abstract][Full Text] [Related]
39. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection. Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124 [TBL] [Abstract][Full Text] [Related]
40. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Limaye AP; Bakthavatsalam R; Kim HW; Randolph SE; Halldorson JB; Healey PJ; Kuhr CS; Levy AE; Perkins JD; Reyes JD; Boeckh M Transplantation; 2006 Jun; 81(12):1645-52. PubMed ID: 16794529 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]